| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;117:1997-2008.)
© 2008 American Heart Association, Inc.
Transplantation |
From the Donald W. Reynolds Cardiovascular Clinical Research Center, Cardiovascular Division, Department of Medicine (K.S., P.L., R.S.) and Department of Pathology (K.A., R.N.M.), Brigham and Womens Hospital, Harvard Medical School, Boston, Mass, and Division of Cardiovascular Medicine, University Hospitals of Cleveland–Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (M.S., Y.W., D.I.S.).
Correspondence to Koichi Shimizu, MD, PhD, Cardiovascular Division, Brigham and Womens Hospital, Harvard Medical School, 77 Ave Louis Pasteur, NRB7, Boston, MA 02115. E-mail ksmz{at}rics.bwh.harvard.edu
Received June 28, 2007; accepted February 13, 2008.
Background— In allograft rejection, recipient leukocytes and alloantibodies first target donor endothelial cells. Although the leukocyte integrin Mac-1 (
Mβ2, CD11b/CD18) facilitates cell–cell interactions among leukocytes and interactions between leukocytes and endothelial cells or platelets, its role in allograft survival and vasculopathy is incompletely defined.
Methods and Results— This study examined parenchymal rejection and graft arterial disease after total allomismatched cardiac transplantation (BALB/c donor heart and B6 recipients) in wild-type (WT) and Mac-1-deficient (Mac-1–/–) recipients. Recipient Mac-1 deficiency attenuated parenchymal rejection and significantly prolonged cardiac allograft survival from 8.3±1.3 days in WT recipient allografts (n=18) to 13.8±2.3 days in Mac-1–/– recipient allografts (n=6; P<0.0001). Accumulation of neutrophils and macrophages significantly decreased in Mac-1–/– compared with WT recipients. Adoptive transfer of WT but not Mac-1–/– macrophages to Mac-1–/– recipients exacerbated parenchymal rejection and reduced allograft survival; in contrast, adoptive transfer of WT neutrophils did not affect graft survival. Mac-1–/– macrophages expressed significantly lower levels of costimulatory molecules both in vivo and in vitro, and mixed lymphocyte reaction using alloantigen-primed Mac-1–/– macrophages resulted in significantly lower antigen-presenting function than for WT macrophages. Tumor necrosis factor-
production also fell in cultures with Mac-1–/– macrophages. Despite attenuation of acute rejection, recipient Mac-1-deficiency did not prevent late graft arterial disease.
Conclusions— These studies demonstrate critical participation of Mac-1 in alloresponses during cellular allograft rejection. These observations establish a molecular target for modulating recipient responses to prolong graft survival.
Related Article:
This article has been cited by other articles:
![]() |
N. Huser, A. Fasan, M. Semmrich, P. Schmidbauer, B. Holzmann, and M. Laschinger Intact LFA-1 deactivation promotes T-cell activation and rejection of cardiac allograft Int. Immunol., November 27, 2009; (2009) dxp111v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nahrendorf, E. Keliher, P. Panizzi, H. Zhang, S. Hembrador, J.-L. Figueiredo, E. Aikawa, K. Kelly, P. Libby, and R. Weissleder 18F-4V for PET-CT Imaging of VCAM-1 Expression in Atherosclerosis J. Am. Coll. Cardiol. Img., October 1, 2009; 2(10): 1213 - 1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Christen, M. Nahrendorf, M. Wildgruber, F. K. Swirski, E. Aikawa, P. Waterman, K. Shimizu, R. Weissleder, and P. Libby Molecular Imaging of Innate Immune Cell Function in Transplant Rejection Circulation, April 14, 2009; 119(14): 1925 - 1932. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shimizu and R. N. Mitchell The Role of Chemokines in Transplant Graft Arterial Disease Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1937 - 1949. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |